These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35292660)

  • 21. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
    Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
    Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
    Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of CD40 ligand in costimulation and T-cell activation.
    Grewal IS; Flavell RA
    Immunol Rev; 1996 Oct; 153():85-106. PubMed ID: 9010720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
    Morales-Molina A; Gambera S; Leo A; García-Castro J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
    Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
    Olguín-Contreras LF; Mendler AN; Popowicz G; Hu B; Noessner E
    Front Immunol; 2021; 12():750478. PubMed ID: 34912334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
    Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
    Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.
    Soong RS; Song L; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
    PLoS One; 2014; 9(3):e93162. PubMed ID: 24664420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells.
    Dotti G; Savoldo B; Yotnda P; Rill D; Brenner MK
    Blood; 2002 Jul; 100(1):200-7. PubMed ID: 12070028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
    Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
    Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.